It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab.
His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria patients previously inadequately controlled with omalizumab; analysis of the Phase 2 program’ was presented at the EADV Virtual Congress, 29-31 October 2020.
- What are the limitations of the current standard of care for chronic spontaneous urticaria? (0:16)
- What is the rationale for the use of ocrelizumab in chronic spontaneous urticaria patients previously inadequately controlled with H1-antihistamines? (0:40)
- Could give us a brief overview of the 2019 Phase II study and its findings? (1:26)
- What have we learned from your recent analyses of this study’s data in terms of possible predictors of response to ligelizumab? (2:18)
- What are the implications of these findings and what further study is needed? (3:06)
Disclosures: Martin Metz was an investigator of this phase II study and has acted as a speaker/ consultant for Novartis.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of EADV Virtual Congress 2020
Share this Video
Related Videos In Dermatological Conditions
Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prognosis, current treatment paradigm & pipeline therapies
The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!